Peak Retirement Planning Inc. Takes Position in United Therapeutics Corporation $UTHR

Peak Retirement Planning Inc. purchased a new stake in shares of United Therapeutics Corporation (NASDAQ:UTHR) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 5,581 shares of the biotechnology company’s stock, valued at approximately $2,719,000.

Other large investors also recently bought and sold shares of the company. Natixis Advisors LLC raised its stake in United Therapeutics by 0.5% in the fourth quarter. Natixis Advisors LLC now owns 11,768 shares of the biotechnology company’s stock worth $5,734,000 after buying an additional 53 shares in the last quarter. Florida Financial Advisors LLC raised its stake in United Therapeutics by 5.4% in the fourth quarter. Florida Financial Advisors LLC now owns 550 shares of the biotechnology company’s stock worth $268,000 after buying an additional 28 shares in the last quarter. Rothschild Wealth LLC bought a new position in United Therapeutics in the fourth quarter worth approximately $337,000. Waterloo Capital L.P. bought a new position in United Therapeutics in the fourth quarter worth approximately $214,000. Finally, Nomura Asset Management Co. Ltd. raised its stake in United Therapeutics by 65.2% in the fourth quarter. Nomura Asset Management Co. Ltd. now owns 21,392 shares of the biotechnology company’s stock worth $10,423,000 after buying an additional 8,446 shares in the last quarter. Institutional investors own 94.08% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts recently commented on the stock. Morgan Stanley set a $516.00 price objective on shares of United Therapeutics in a research note on Thursday, May 7th. Raymond James Financial assumed coverage on shares of United Therapeutics in a research note on Friday, April 10th. They issued an “outperform” rating and a $700.00 price objective for the company. Wells Fargo & Company raised shares of United Therapeutics from an “equal weight” rating to an “overweight” rating and boosted their price objective for the stock from $575.00 to $735.00 in a research note on Thursday, May 7th. HC Wainwright boosted their price objective on shares of United Therapeutics from $600.00 to $660.00 and gave the stock a “buy” rating in a research note on Tuesday, March 31st. Finally, Cantor Fitzgerald boosted their price objective on shares of United Therapeutics from $525.00 to $625.00 and gave the stock an “overweight” rating in a research note on Thursday, March 12th. Eleven analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $619.42.

United Therapeutics Stock Performance

United Therapeutics stock opened at $540.05 on Wednesday. The stock has a 50-day moving average of $566.86 and a two-hundred day moving average of $516.87. United Therapeutics Corporation has a one year low of $272.12 and a one year high of $609.35. The stock has a market cap of $22.93 billion, a PE ratio of 19.94, a price-to-earnings-growth ratio of 1.77 and a beta of 0.57.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 EPS for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The business had revenue of $781.50 million during the quarter, compared to analysts’ expectations of $797.40 million. During the same quarter last year, the business posted $6.63 earnings per share. The company’s quarterly revenue was down 1.6% compared to the same quarter last year. As a group, sell-side analysts predict that United Therapeutics Corporation will post 26.92 EPS for the current fiscal year.

Insider Buying and Selling at United Therapeutics

In other news, CFO James Edgemond sold 10,000 shares of the business’s stock in a transaction on Monday, June 1st. The shares were sold at an average price of $547.87, for a total transaction of $5,478,700.00. Following the sale, the chief financial officer directly owned 18,876 shares of the company’s stock, valued at $10,341,594.12. The trade was a 34.63% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Paul A. Mahon sold 8,300 shares of the business’s stock in a transaction on Thursday, May 21st. The shares were sold at an average price of $562.82, for a total transaction of $4,671,406.00. Following the sale, the executive vice president directly owned 45,172 shares in the company, valued at $25,423,705.04. This trade represents a 15.52% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 614,043 shares of company stock worth $344,991,997. 8.60% of the stock is owned by insiders.

United Therapeutics Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.